A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.
Also called NCT05018650
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 250 participants
- Sponsor
- Route 92 Medical, Inc.
- Registry
-
NCT05018650
-
- Other papers using this trial's data
- SUMMIT MAX: A Randomized Trial of the Super Large Bore HiPoint Reperfusion System Versus Vecta System for Aspiration Thrombectomy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT05018650. Randomized; no masking; primary purpose treatment. Start 2021-12-21 (actual); primary completion 2024-02-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)
- Condition
- Acute Ischemic Stroke
- Intervention (Device)
- Route 92 Medical Reperfusion System
- Lead sponsor
- Route 92 Medical, Inc.
Record details
- Record id
cardio:ct-nct05018650- Content hash
0b7c169d73b44f42f9c80184cb3bbb1ecc68f189ee4f15af92bb4a86c3908dee